Categories: CancerDiagnosticsNews

EDAP TMS SA to Announce Second Quarter 2022 Financial Results on August 24th, 2022

Company to host conference call and webcast on Thursday, August 25that 8:30 am EDT

LYON, France, August 3, 2022 – EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30th after the markets close on Wednesday, August 24th, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, August 25th, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Thursday, August 25th@ 8:30am Eastern Time
Domestic:        877-451-6152
International:        201-389-0879
Passcode:        13731177
Webcast:        https://viavid.webcasts.com/starthere.jsp?ei=1558239&tp_key=295933838c

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Company contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
212-915-2568
jfraunces@lifesciadvisors.com

 

Staff

Recent Posts

Yuwell Medical Makes Its Debut at CES 2026: AI Expands the Boundaries of Health Management

LAS VEGAS, Jan. 8, 2026 /PRNewswire/ -- From January 6 to 9, CES 2026, held in…

5 hours ago

Proximity Health Solutions and Biogen Named Finalists for the SCOPE ’26 Participant Engagement Award

STAMFORD, Conn., Jan. 8, 2026 /PRNewswire/ -- Proximity Health Solutions, in collaboration with Biogen, announces that…

11 hours ago

In HelloNation, Personal Injury Attorney Professional Joseph Miklos of Garden City, NY, Launches New Expert Website Highlighting His Work in the Community

GARDEN CITY, N.Y., Jan. 8, 2026 /PRNewswire/ -- What defines a Personal Injury Attorney Professional…

11 hours ago

Therap’s Individual Home Page Integrates Person-Centered Data for Comprehensive Care Management

TORRINGTON, Conn., Jan. 8, 2026 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…

11 hours ago

FUGO Precision 3D and Graphy Forge Strategic Partnership to Accelerate Advanced Material Integration Ahead of LMT 2026 Launch

GARDENA, Calif., Jan. 8, 2026 /PRNewswire/ -- FUGO Precision 3D, a pioneering force in next-generation…

11 hours ago